Anti-fibrotic effect of isorhamnetin and its derivatives on disruption of pancreatic ductal adenocarcinoma desmoplasia by regulation of cancer-associated fibroblasts

Research Project

Project/Area Number	21K14789
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 38030:Applied biochemistry-related
Research Institution	National Institute of Advanced Industrial Science and Technology
Principal Investigator	Ganbold Munkhzul 国立研究開発法人産業技術総合研究所, 材料・化学領域, 産総研特別研究員 (00882169)
Project Period (FY)	2021-04-01 – 2024-03-31
Project Status	Granted (Fiscal Year 2021)
Budget Amount *help	¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000) Fiscal Year 2023: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2022: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000) Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords	Isorhamnetin / PDAC / pancreatic cancer / CAF / quercetin derivative
Outline of Research at the Start	A wide range of in vitro studies using human PDAC cell lines and human immortalized CAFs derived from PDAC patients will be conducted to study the effect of isorhamnetin and its derivatives in a more realistic environment.